Dr Mead on the Use of Zanubrutinib vs Ibrutinib in MCL

Monica D. Mead, MD, discusses the efficacy and safety differences between the second-generation BTK inhibitor zanubrutinib and the first-generation BTK inhibitor ibrutinib in patients with mantle cell lymphoma.

Related Keywords

Los Angeles ,California ,United States ,Monicad Mead , ,University Of California ,Jonsson Comprehensive Cancer Center ,Hematologic Malignancy ,Comprehensive Cancer Center ,D ,Ucla Jonsson Comprehensive Cancer Center ,